{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Gastrointestinal+Carcinoma&page=60",
    "query": {
      "condition": "Gastrointestinal Carcinoma",
      "page": 60
    },
    "page_size": 10
  },
  "pagination": {
    "page": 60,
    "page_size": 10,
    "total_count": 2729,
    "total_pages": 273,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Gastrointestinal+Carcinoma&page=61&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Gastrointestinal+Carcinoma&page=59&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-20T02:59:35.021Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05651022",
      "title": "Study of DECOY20 With or Without Tislelizumab in Patients With Advanced Solid Tumors",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Solid Tumor, Adult",
        "HCC - Hepatocellular Carcinoma",
        "CRC (Colorectal Cancer)",
        "Pancreatic Adenocarcinoma",
        "NSCLC Non-small Cell Lung Cancer",
        "Squamous Cell Cancer of the Head and Neck",
        "UC (Urothelial Cancer)",
        "MSI-H Cancer"
      ],
      "interventions": [
        {
          "name": "Decoy20",
          "type": "DRUG"
        },
        {
          "name": "Tislelizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Indaptus Therapeutics, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 120,
      "start_date": "2023-02-28",
      "completion_date": "2027-09-30",
      "has_results": false,
      "last_update_posted_date": "2026-01-13",
      "last_synced_at": "2026-10-20T02:59:35.021Z",
      "location_count": 12,
      "location_summary": "Los Angeles, California • Newport Beach, California • Atlanta, Georgia + 8 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05651022"
    },
    {
      "nct_id": "NCT07776353",
      "title": "Understanding New Cachexia Subtypes Through Observational Epidemiological Research",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Advanced Colorectal Carcinoma",
        "Advanced Lung Non-Small Cell Carcinoma",
        "Advanced Pancreatic Adenocarcinoma",
        "Stage IV Colorectal Cancer AJCC v8",
        "Stage IV Lung Cancer AJCC v8",
        "Stage IV Pancreatic Cancer AJCC v8",
        "Unresectable Colorectal Carcinoma",
        "Unresectable Lung Non-Small Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Electronic health record review",
          "type": "OTHER"
        },
        {
          "name": "Medical Device Usage and Evaluation",
          "type": "OTHER"
        },
        {
          "name": "Physical functions assessments",
          "type": "OTHER"
        },
        {
          "name": "Positron Emission Tomography (PET)",
          "type": "PROCEDURE"
        },
        {
          "name": "Survey Administration",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "OTHER"
      ],
      "sponsor": "Kaiser Permanente",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 800,
      "start_date": "2023-04-05",
      "completion_date": "2028-05",
      "has_results": false,
      "last_update_posted_date": "2026-08-20",
      "last_synced_at": "2026-10-20T02:59:35.021Z",
      "location_count": 1,
      "location_summary": "Pleasanton, California",
      "locations": [
        {
          "city": "Pleasanton",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07776353"
    },
    {
      "nct_id": "NCT07283939",
      "title": "Studying the PAGODA Algorithm for Chemotherapy Dose Changes to Prevent Unplanned Treatment Delays",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Ampulla of Vater Carcinoma",
        "Appendix Carcinoma",
        "Carcinoma of Unknown Primary With Gastrointestinal Profile",
        "Colon Carcinoma",
        "Esophageal Carcinoma",
        "Gastric Carcinoma",
        "Gastroesophageal Junction Carcinoma",
        "Malignant Digestive System Neoplasm",
        "Rectal Carcinoma",
        "Small Intestinal Carcinoma"
      ],
      "interventions": [
        {
          "name": "PAGODA algorithm",
          "type": "OTHER"
        },
        {
          "name": "Oxaliplatin",
          "type": "DRUG"
        },
        {
          "name": "Folinic Acid",
          "type": "DRUG"
        },
        {
          "name": "Fluorouracil",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "OTHER",
        "DRUG"
      ],
      "sponsor": "Alliance for Clinical Trials in Oncology",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 420,
      "start_date": "2026-02-13",
      "completion_date": "2030-05-02",
      "has_results": false,
      "last_update_posted_date": "2026-10-02",
      "last_synced_at": "2026-10-20T02:59:35.021Z",
      "location_count": 360,
      "location_summary": "Fairbanks, Alaska • Phoenix, Arizona • Fort Smith, Arkansas + 268 more",
      "locations": [
        {
          "city": "Fairbanks",
          "state": "Alaska"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Fort Smith",
          "state": "Arkansas"
        },
        {
          "city": "Jonesboro",
          "state": "Arkansas"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07283939"
    },
    {
      "nct_id": "NCT05283330",
      "title": "Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Cervical Cancer",
        "Breast Cancer",
        "Colon Cancer",
        "NSCLC",
        "mCRPC (Metastatic Castration-resistant Prostate Cancer)",
        "Glioblastoma",
        "Nonsmall Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "²¹²Pb-DOTAM-GRPR1",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Orano Med Theranostics, SAS",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 48,
      "start_date": "2022-12-22",
      "completion_date": "2032-05",
      "has_results": false,
      "last_update_posted_date": "2026-06-11",
      "last_synced_at": "2026-10-20T02:59:35.021Z",
      "location_count": 8,
      "location_summary": "Chicago, Illinois • Iowa City, Iowa • Lexington, Kentucky + 3 more",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        },
        {
          "city": "Lexington",
          "state": "Kentucky"
        },
        {
          "city": "Glen Burnie",
          "state": "Maryland"
        },
        {
          "city": "Glen Burnie",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05283330"
    },
    {
      "nct_id": "NCT04476329",
      "title": "Optimization for Regorafenib in HCC",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hepatocellular Carcinoma"
      ],
      "interventions": [
        {
          "name": "Regorafenib 40 MG",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "SC Liver Research Consortium, LLC",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 7,
      "start_date": "2021-01-21",
      "completion_date": "2021-12-10",
      "has_results": false,
      "last_update_posted_date": "2021-12-30",
      "last_synced_at": "2026-10-20T02:59:35.021Z",
      "location_count": 9,
      "location_summary": "Gilbert, Arizona • Long Beach, California • New Orleans, Louisiana + 6 more",
      "locations": [
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "New Orleans",
          "state": "Louisiana"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "Grand Rapids",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04476329"
    },
    {
      "nct_id": "NCT04605731",
      "title": "Durvalumab and Tremelimumab After Radioembolization for the Treatment of Unresectable, Locally Advanced Liver Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "BCLC Stage B Hepatocellular Carcinoma",
        "BCLC Stage C Hepatocellular Carcinoma",
        "Locally Advanced Hepatocellular Carcinoma",
        "Stage III Hepatocellular Carcinoma AJCC v8",
        "Stage IIIA Hepatocellular Carcinoma AJCC v8",
        "Stage IIIB Hepatocellular Carcinoma AJCC v8",
        "Stage IV Hepatocellular Carcinoma AJCC v8",
        "Stage IVA Hepatocellular Carcinoma AJCC v8",
        "Stage IVB Hepatocellular Carcinoma AJCC v8",
        "Unresectable Hepatocellular Carcinoma"
      ],
      "interventions": [
        {
          "name": "Durvalumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Tremelimumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "City of Hope Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 25,
      "start_date": "2021-08-03",
      "completion_date": "2027-02-23",
      "has_results": false,
      "last_update_posted_date": "2026-04-20",
      "last_synced_at": "2026-10-20T02:59:35.021Z",
      "location_count": 1,
      "location_summary": "Duarte, California",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04605731"
    },
    {
      "nct_id": "NCT00725712",
      "title": "Study of GSK1363089 in Metastatic Gastric Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Neoplasms, Gastrointestinal Tract"
      ],
      "interventions": [
        {
          "name": "GSK1363089 (formerly XL880)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 74,
      "start_date": "2007-03-31",
      "completion_date": "2009-11-30",
      "has_results": true,
      "last_update_posted_date": "2017-08-24",
      "last_synced_at": "2026-10-20T02:59:35.021Z",
      "location_count": 17,
      "location_summary": "Birmingham, Alabama • Scottsdale, Arizona • Los Angeles, California + 13 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00725712"
    },
    {
      "nct_id": "NCT02620800",
      "title": "Study of 5-fluorouracil (5-FU), Nab®1-paclitaxel, Bevacizumab, Leucovorin, and Oxaliplatin in Patients With Metastatic Pancreatic Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Metastatic Pancreas Adenocarcinoma"
      ],
      "interventions": [
        {
          "name": "5FU",
          "type": "DRUG"
        },
        {
          "name": "nab-paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "bevacizumab",
          "type": "DRUG"
        },
        {
          "name": "calcium leucovorin",
          "type": "DRUG"
        },
        {
          "name": "oxaliplatin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Celgene",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 12,
      "start_date": "2016-01-18",
      "completion_date": "2018-10-29",
      "has_results": false,
      "last_update_posted_date": "2019-10-22",
      "last_synced_at": "2026-10-20T02:59:35.021Z",
      "location_count": 7,
      "location_summary": "Chicago, Illinois • Boston, Massachusetts • Ann Arbor, Michigan + 4 more",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02620800"
    },
    {
      "nct_id": "NCT02524119",
      "title": "LEE001 and Chemoembolization In Patients With Advanced Hepatocellular Carcinoma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hepatocellular Carcinoma"
      ],
      "interventions": [
        {
          "name": "LEE011",
          "type": "DRUG"
        },
        {
          "name": "Chemoembolization",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "University of Texas Southwestern Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 5,
      "start_date": "2016-04",
      "completion_date": "2020-09",
      "has_results": true,
      "last_update_posted_date": "2021-02-01",
      "last_synced_at": "2026-10-20T02:59:35.021Z",
      "location_count": 1,
      "location_summary": "Dallas, Texas",
      "locations": [
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02524119"
    },
    {
      "nct_id": "NCT00589030",
      "title": "Yttrium Y 90 Radiolabeled Glass Beads in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery",
      "overall_status": "NO_LONGER_AVAILABLE",
      "study_type": "EXPANDED_ACCESS",
      "phases": [],
      "conditions": [
        "Liver Cancer"
      ],
      "interventions": [
        {
          "name": "brachytherapy",
          "type": "RADIATION"
        },
        {
          "name": "yttrium Y 90 glass microspheres",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "RADIATION"
      ],
      "sponsor": "City of Hope Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": null,
      "start_date": "2007-04",
      "completion_date": "2014-09",
      "has_results": false,
      "last_update_posted_date": "2017-02-15",
      "last_synced_at": "2026-10-20T02:59:35.021Z",
      "location_count": 1,
      "location_summary": "Duarte, California",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00589030"
    }
  ]
}